Antisense Oligonucleotide–Mediated MSH3 Suppression Reduces Somatic CAG Repeat Expansion in Huntington’s Disease iPSC–Derived Striatal Neurons

Therapeutic Potential of ASO-Mediated MSH3 Suppression in Huntington’s Disease Academic Background Huntington’s disease (HD) is a neurodegenerative disorder caused by abnormal expansion of the CAG repeat sequence in the huntingtin gene (HTT). This expanded CAG repeat continues to expand somatically over time, driving the onset and progression of th...

Phase 1/2 Trial of Brogidirsen: Dual-Targeting Antisense Oligonucleotides for Exon 44 Skipping in Duchenne Muscular Dystrophy

New Advances in Dual-Targeting Antisense Oligonucleotide Therapy for Duchenne Muscular Dystrophy: Phase 1⁄2 Clinical Trial of Brogidirsen Background Duchenne Muscular Dystrophy (DMD) is a fatal genetic disorder primarily affecting skeletal and cardiac muscles, leading to early loss of mobility and, eventually, organ failure. Currently, there is no ...

GYS1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model

GYS1 Antisense Therapy Inhibits Pathogenic Aggregates and Epileptiform Discharges in a Mouse Model of Lafora Disease Background and Objectives Lafora disease (LD) is a devastating autosomal recessive genetic disorder characterized by epilepsy and rapidly progressive dementia in adolescence. The disease primarily involves mutations in the EPM2A or E...